Targeting α-Klotho Protein by Agmatine and Pioglitazone Is a New Avenue against Diabetic Nephropathy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Experimental analysis reveals agmatine and pioglitazone reduce diabetic nephropathy markers, suggesting α-klotho modulation is effective.

Agmatine and pioglitazone significantly improved blood glucose levels and renal function in diabetic nephropathy models.
Combined treatment reduced inflammatory markers and oxidative stress, enhancing renal health in diabetic rats.
An intraperitoneal injection model simulating diabetic nephropathy revealed mechanistic insights into α-klotho modulation.
These findings highlight the potential of agmatine and pioglitazone as novel treatments for diabetic nephropathy.

Azar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Experimental analysis reveals agmatine and pioglitazone reduce diabetic nephropathy markers, suggesting α-klotho modulation is effective.